- Home
- CYCU vs SBFM Comparison
CYCU vs SBFM Comparison
Compare CYCU & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCU
- SBFM
- Stock Information
- Founded
- CYCU N/A
- SBFM 2006
- Country
- CYCU United States
- SBFM United States
- Employees
- CYCU N/A
- SBFM N/A
- Industry
- CYCU
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- CYCU
- SBFM Health Care
- Exchange
- CYCU Nasdaq
- SBFM Nasdaq
- Market Cap
- CYCU 6.0M
- SBFM 4.9M
- IPO Year
- CYCU N/A
- SBFM N/A
- Fundamental
- Price
- CYCU $0.48
- SBFM $1.55
- Analyst Decision
- CYCU
- SBFM Strong Buy
- Analyst Count
- CYCU 0
- SBFM 1
- Target Price
- CYCU N/A
- SBFM $15.00
- AVG Volume (30 Days)
- CYCU 9.5M
- SBFM 4.3M
- Earning Date
- CYCU 05-15-2025
- SBFM 05-19-2025
- Dividend Yield
- CYCU N/A
- SBFM N/A
- EPS Growth
- CYCU N/A
- SBFM N/A
- EPS
- CYCU 0.02
- SBFM N/A
- Revenue
- CYCU $17,771,485.00
- SBFM $34,874,283.00
- Revenue This Year
- CYCU N/A
- SBFM $192.48
- Revenue Next Year
- CYCU N/A
- SBFM N/A
- P/E Ratio
- CYCU $28.53
- SBFM N/A
- Revenue Growth
- CYCU N/A
- SBFM 44.75
- 52 Week Low
- CYCU $0.42
- SBFM $1.17
- 52 Week High
- CYCU $10.99
- SBFM $33.60
- Technical
- Relative Strength Index (RSI)
- CYCU N/A
- SBFM 44.81
- Support Level
- CYCU N/A
- SBFM $1.17
- Resistance Level
- CYCU N/A
- SBFM $1.59
- Average True Range (ATR)
- CYCU 0.00
- SBFM 0.19
- MACD
- CYCU 0.00
- SBFM 0.03
- Stochastic Oscillator
- CYCU 0.00
- SBFM 52.84
About CYCU Cycurion Inc. Common Stock
Cycurion Inc. provides premier information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.